Q1 Earnings Forecast for Exelixis Issued By Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Analysts at Leerink Partnrs boosted their Q1 2025 earnings estimates for Exelixis in a report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will earn $0.36 per share for the quarter, up from their prior forecast of $0.35. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Leerink Partnrs also issued estimates for Exelixis' Q2 2025 earnings at $0.50 EPS, Q4 2025 earnings at $0.68 EPS and FY2025 earnings at $2.15 EPS.

Other equities analysts have also recently issued reports about the stock. StockNews.com raised shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 19th. Brookline Capital Management initiated coverage on Exelixis in a research note on Monday, December 23rd. They set a "buy" rating on the stock. Royal Bank of Canada raised their price target on Exelixis from $38.00 to $40.00 and gave the stock an "outperform" rating in a research note on Thursday, March 13th. Barclays raised their price target on Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. Finally, Stephens reiterated an "equal weight" rating and set a $29.00 target price on shares of Exelixis in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $37.59.

Remove Ads

Exelixis Stock Performance

NASDAQ:EXEL traded down $0.50 during trading hours on Friday, reaching $36.42. The stock had a trading volume of 868,577 shares, compared to its average volume of 2,137,959. The stock has a market capitalization of $10.19 billion, a PE ratio of 20.60, a PEG ratio of 1.13 and a beta of 0.57. Exelixis has a 52 week low of $20.14 and a 52 week high of $40.02. The company has a 50 day moving average price of $35.72 and a two-hundred day moving average price of $33.39.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now owns 341,028 shares in the company, valued at $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack L. Wyszomierski sold 8,768 shares of the firm's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $37.80, for a total transaction of $331,430.40. Following the transaction, the director now directly owns 356,605 shares of the company's stock, valued at approximately $13,479,669. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock worth $5,177,234 in the last three months. Corporate insiders own 2.85% of the company's stock.

Institutional Trading of Exelixis

A number of hedge funds have recently bought and sold shares of EXEL. Coppell Advisory Solutions LLC acquired a new position in shares of Exelixis in the 4th quarter valued at $25,000. Colonial Trust Co SC grew its stake in shares of Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 765 shares in the last quarter. Principal Securities Inc. raised its position in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares in the last quarter. USA Financial Formulas acquired a new stake in Exelixis during the fourth quarter worth approximately $32,000. Finally, Kestra Investment Management LLC purchased a new stake in Exelixis in the fourth quarter valued at $39,000. Institutional investors and hedge funds own 85.27% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.